Clinical Trial Update: Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for MONITOR-AF investigating mineralocorticoid antagonism to halt progression of atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Atrial Fibrillation | Phase 2 | Status: UNKNOWN